Introduction: Ketamine has emerged as a rapid-acting antidepressant. While ongoing treatment can prevent relapse, concerns exist regarding long-term exposure. Objective: We conducted a randomized trial to examine the feasibility and efficacy of cognitive behavioral therapy (CBT) following intravenous ketamine in treatment-resistant depression (TRD). Methods: Subjects with TRD were recruited and treated with 6 intravenous infusions of ketamine over 3 weeks. Subjects who experienced a clinical response (≥50% improvement in depression severity) were then randomized to receiving CBT or treatment as usual (TAU) for an additional 14 weeks, using a sequential treatment model. Results: Of the 42 patients who signed consent, 28 patients achieved a response and were randomized to CBT or TAU. When measured using the Montgomery-Asberg Depression Rating Scale (primary outcome measure), the effect size at the end of the study was moderate (Cohen d = 0.65; 95% CI –0.55 to 1.82), though the group-by-time interaction effect was not significant. There was a significant group-by-time interaction as measured by the Quick Inventory of Depressive Symptomatology (F = 4.58; p = 0.033), favoring a greater sustained improvement in the CBT group. This corresponded to a moderate-to-large effect size of the Cohen d = 0.71 (95% CI –0.30 to 1.70) at the end of the study (14 weeks following the last ketamine infusion). In a subset of patients (N = 20) who underwent cognitive testing using the emotional N-back assessments before and after ketamine, ketamine responders showed improvement in the accuracy of emotional N-back (t[8] = 2.33; p < 0.05) whereas nonresponders did not (t[10] <1; p ns). Conclusions: This proof-of-concept study provides preliminary data indicating that CBT may sustain the antidepressant effects of ketamine in TRD. Further study and optimization of this treatment approach in well-powered clinical trials is recommended.

1.
Kim
J
,
Farchione
T
,
Potter
A
,
Chen
Q
,
Temple
R
.
Esketamine for treatment-resistant depression - first FDA-approved antidepressant in a new class
.
N Engl J Med
.
2019
Jul
;
381
(
1
):
1
4
.
[PubMed]
1533-4406
2.
Daly
EJ
,
Trivedi
MH
,
Janik
A
,
Li
H
,
Zhang
Y
,
Li
X
, et al.
Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial
.
JAMA Psychiatry
.
2019
Sep
;
76
(
9
):
893
903
.
[PubMed]
2168-6238
3.
Wilkinson
ST
,
Howard
DH
,
Busch
SH
.
Psychiatric practice patterns and barriers to the adoption of esketamine
.
JAMA
.
2019
Sep
;
322
(
11
):
1039
40
.
[PubMed]
1538-3598
4.
Food and Drug Administration
.
Spravato Prescribing Information
[cited 2021 Mar 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243lbl.pdf
5.
Wajs
E
,
Aluisio
L
,
Holder
R
,
Daly
EJ
,
Lane
R
,
Lim
P
, et al.
Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)
.
J Clin Psychiatry
.
2020
Apr
;
81
(
3
):
e1
10
.
[PubMed]
1555-2101
6.
Schatzberg
AF
.
A word to the wise about intranasal esketamine
.
Am J Psychiatry
.
2019
Jun
;
176
(
6
):
422
4
.
[PubMed]
1535-7228
7.
Murrough
JW
,
Perez
AM
,
Pillemer
S
,
Stern
J
,
Parides
MK
,
aan het Rot
M
, et al.
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression
.
Biol Psychiatry
.
2013
Aug
;
74
(
4
):
250
6
.
[PubMed]
1873-2402
8.
Li
N
,
Lee
B
,
Liu
RJ
,
Banasr
M
,
Dwyer
JM
,
Iwata
M
, et al.
mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists
.
Science
.
2010
Aug
;
329
(
5994
):
959
64
.
[PubMed]
1095-9203
9.
Zanos
P
,
Moaddel
R
,
Morris
PJ
,
Georgiou
P
,
Fischell
J
,
Elmer
GI
, et al.
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
.
Nature
.
2016
May
;
533
(
7604
):
481
6
.
[PubMed]
1476-4687
10.
Williams
NR
,
Heifets
BD
,
Blasey
C
,
Sudheimer
K
,
Pannu
J
,
Pankow
H
, et al.
Attenuation of antidepressant effects of ketamine by opioid receptor antagonism
.
Am J Psychiatry
.
2018
Dec
;
175
(
12
):
1205
15
.
[PubMed]
1535-7228
11.
Jett
JD
,
Boley
AM
,
Girotti
M
,
Shah
A
,
Lodge
DJ
,
Morilak
DA
.
Antidepressant-like cognitive and behavioral effects of acute ketamine administration associated with plasticity in the ventral hippocampus to medial prefrontal cortex pathway
.
Psychopharmacology (Berl)
.
2015
Sep
;
232
(
17
):
3123
33
.
[PubMed]
1432-2072
12.
Paredes
D
,
Silva
JD
,
Morilak
DA
.
Ketamine corrects a deficit in reversal learning caused by chronic intermittent cold stress in female rats
.
Int J Neuropsychopharmacol
.
2018
Dec
;
21
(
12
):
1109
13
.
[PubMed]
1469-5111
13.
Patton
MS
,
Lodge
DJ
,
Morilak
DA
,
Girotti
M
.
Ketamine corrects stress-induced cognitive dysfunction through JAK2/STAT3 signaling in the orbitofrontal cortex
.
Neuropsychopharmacology
.
2017
May
;
42
(
6
):
1220
30
.
[PubMed]
1740-634X
14.
Uddin
LQ
.
Cognitive and behavioural flexibility: neural mechanisms and clinical considerations
.
Nat Rev Neurosci
.
2021
Mar
;
22
(
3
):
167
79
.
[PubMed]
1471-0048
15.
Wilkinson
ST
,
Wright
D
,
Fasula
MK
,
Fenton
L
,
Griepp
M
,
Ostroff
RB
, et al.
Cognitive Behavior Therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression
.
Psychother Psychosom
.
2017
;
86
(
3
):
162
7
.
[PubMed]
1423-0348
16.
Wilkinson
ST
,
Holtzheimer
PE
,
Gao
S
,
Kirwin
DS
,
Price
RB
.
Leveraging neuroplasticity to enhance adaptive learning: the potential for synergistic somatic-behavioral treatment combinations to improve clinical outcomes in depression
.
Biol Psychiatry
.
2019
Mar
;
85
(
6
):
454
65
.
[PubMed]
1873-2402
17.
Hollon
SD
,
DeRubeis
RJ
,
Shelton
RC
,
Amsterdam
JD
,
Salomon
RM
,
O’Reardon
JP
, et al.
Prevention of relapse following cognitive therapy vs medications in moderate to severe depression
.
Arch Gen Psychiatry
.
2005
Apr
;
62
(
4
):
417
22
.
[PubMed]
0003-990X
18.
Sim
K
,
Lau
WK
,
Sim
J
,
Sum
MY
,
Baldessarini
RJ
.
Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analyses of controlled trials
.
Int J Neuropsychopharmacol
.
2015
Jul
;
19
(
2
):pyv076.
[PubMed]
1469-5111
19.
Guidi
J
,
Tomba
E
,
Fava
GA
.
The sequential integration of pharmacotherapy and psychotherapy in the treatment of major depressive disorder: a meta-analysis of the sequential model and a critical review of the literature
.
Am J Psychiatry
.
2016
Feb
;
173
(
2
):
128
37
.
[PubMed]
1535-7228
20.
Guidi
J
,
Fava
GA
.
Sequential combination of pharmacotherapy and psychotherapy in major depressive disorder: a systematic review and meta-analysis
.
JAMA Psychiatry
.
2021
Mar
;
78
(
3
):
261
9
.
[PubMed]
2168-6238
21.
Chandler
GM
,
Iosifescu
DV
,
Pollack
MH
,
Targum
SD
,
Fava
M
.
RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ)
.
CNS Neurosci Ther
.
2010
Oct
;
16
(
5
):
322
5
.
[PubMed]
1755-5949
22.
Hamilton
M
.
A rating scale for depression
.
J Neurol Neurosurg Psychiatry
.
1960
Feb
;
23
(
1
):
56
62
.
[PubMed]
0022-3050
23.
Montgomery
SA
,
Asberg
M
.
A new depression scale designed to be sensitive to change
.
Br J Psychiatry
.
1979
Apr
;
134
(
4
):
382
9
.
[PubMed]
0007-1250
24.
Rush
AJ
,
Trivedi
MH
,
Ibrahim
HM
,
Carmody
TJ
,
Arnow
B
,
Klein
DN
, et al.
The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression
.
Biol Psychiatry
.
2003
Sep
;
54
(
5
):
573
83
.
[PubMed]
0006-3223
25.
Kobak
KA
,
Williams
JB
,
Jeglic
E
,
Salvucci
D
,
Sharp
IR
.
Face-to-face versus remote administration of the Montgomery-Asberg Depression Rating Scale using videoconference and telephone
.
Depress Anxiety
.
2008
;
25
(
11
):
913
9
.
[PubMed]
1520-6394
26.
Sanacora
G
,
Fenton
LR
,
Fasula
MK
,
Rothman
DL
,
Levin
Y
,
Krystal
JH
, et al.
Cortical gamma-aminobutyric acid concentrations in depressed patients receiving cognitive behavioral therapy
.
Biol Psychiatry
.
2006
Feb
;
59
(
3
):
284
6
.
[PubMed]
0006-3223
27.
Fenton
L
,
Fasula
M
,
Ostroff
R
,
Sanacora
G
.
Can cognitive behavioral therapy reduce relapse rates of depression after ECT? a preliminary study
.
J ECT
.
2006
Sep
;
22
(
3
):
196
8
.
[PubMed]
1095-0680
28.
Friedman
NP
,
Miyake
A
,
Young
SE
,
DeFries
JC
,
Corley
RP
,
Hewitt
JK
.
Individual differences in executive functions are almost entirely genetic in origin
.
J Exp Psychol Gen
.
2008
May
;
137
(
2
):
201
25
.
[PubMed]
0096-3445
29.
Bradley
MM
,
Lang
PJ
. Affective norms for English words (ANEW): instruction manual and affective ratings. Technical Report C-1, The Center for Research in Psychophysiology, University of Florida;
1999
.
30.
Dozois
DJ
,
Dobson
KS
.
A longitudinal investigation of information processing and cognitive organization in clinical depression: stability of schematic interconnectedness
.
J Consult Clin Psychol
.
2001
Dec
;
69
(
6
):
914
25
.
[PubMed]
0022-006X
31.
Davidson
J
,
Turnbull
CD
,
Strickland
R
,
Miller
R
,
Graves
K
.
The Montgomery-Asberg Depression Scale: reliability and validity
.
Acta Psychiatr Scand
.
1986
May
;
73
(
5
):
544
8
.
[PubMed]
0001-690X
32.
Trivedi
MH
,
Rush
AJ
,
Ibrahim
HM
,
Carmody
TJ
,
Biggs
MM
,
Suppes
T
, et al.
The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation
.
Psychol Med
.
2004
Jan
;
34
(
1
):
73
82
.
[PubMed]
0033-2917
33.
Yang
Z
,
Oathes
DJ
,
Linn
KA
,
Bruce
SE
,
Satterthwaite
TD
,
Cook
PA
, et al.
Cognitive Behavioral Therapy is associated with enhanced cognitive control network activity in major depression and posttraumatic stress disorder
.
Biol Psychiatry Cogn Neurosci Neuroimaging
.
2018
Apr
;
3
(
4
):
311
9
.
[PubMed]
2451-9030
34.
Joormann
J
,
Vanderlind
WM
.
Emotion regulation in depression: the role of biased cognition and reduced cognitive control
.
Clin Psychol Sci
.
2014
;
2
(
4
):
402
21
. 2167-7026
35.
Fales
CL
,
Barch
DM
,
Rundle
MM
,
Mintun
MA
,
Snyder
AZ
,
Cohen
JD
, et al.
Altered emotional interference processing in affective and cognitive-control brain circuitry in major depression
.
Biol Psychiatry
.
2008
Feb
;
63
(
4
):
377
84
.
[PubMed]
1873-2402
36.
Rychlik
M
,
Bollen
E
,
Rygula
R
.
Ketamine decreases sensitivity of male rats to misleading negative feedback in a probabilistic reversal-learning task
.
Psychopharmacology (Berl)
.
2017
Feb
;
234
(
4
):
613
20
.
[PubMed]
1432-2072
37.
Izumi
Y
,
Zorumski
CF
.
Metaplastic effects of subanesthetic ketamine on CA1 hippocampal function
.
Neuropharmacology
.
2014
Nov
;
86
:
273
81
.
[PubMed]
1873-7064
38.
Girgenti
MJ
,
Ghosal
S
,
LoPresto
D
,
Taylor
JR
,
Duman
RS
.
Ketamine accelerates fear extinction via mTORC1 signaling
.
Neurobiol Dis
.
2017
Apr
;
100
:
1
8
.
[PubMed]
1095-953X
39.
Will
CC
,
Aird
F
,
Redei
EE
.
Selectively bred Wistar-Kyoto rats: an animal model of depression and hyper-responsiveness to antidepressants
.
Mol Psychiatry
.
2003
Nov
;
8
(
11
):
925
32
.
[PubMed]
1359-4184
40.
Fortress
AM
,
Smith
IM
,
Pang
KC
.
Ketamine facilitates extinction of avoidance behavior and enhances synaptic plasticity in a rat model of anxiety vulnerability: implications for the pathophysiology and treatment of anxiety disorders
.
Neuropharmacology
.
2018
Jul
;
137
:
372
81
.
[PubMed]
1873-7064
41.
Duman
RS
,
Aghajanian
GK
,
Sanacora
G
,
Krystal
JH
.
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
.
Nat Med
.
2016
Mar
;
22
(
3
):
238
49
.
[PubMed]
1546-170X
42.
Pryazhnikov
E
,
Mugantseva
E
,
Casarotto
P
,
Kolikova
J
,
Fred
SM
,
Toptunov
D
, et al.
Longitudinal two-photon imaging in somatosensory cortex of behaving mice reveals dendritic spine formation enhancement by subchronic administration of low-dose ketamine
.
Sci Rep
.
2018
Apr
;
8
(
1
):
6464
.
[PubMed]
2045-2322
43.
Hasler
G
,
Suker
S
,
Schoretsanitis
G
,
Mihov
Y
.
Sustained improvement of negative self-schema after a single ketamine infusion: an open-label study
.
Front Neurosci
.
2020
Jul
;
14
:
687
.
[PubMed]
1662-4548
44.
Wilkinson
ST
,
Katz
RB
,
Toprak
M
,
Webler
R
,
Ostroff
RB
,
Sanacora
G
.
Acute and longer-term outcomes using ketamine as a clinical treatment at the Yale Psychiatric Hospital
.
J Clin Psychiatry
.
2018
Jul
;
79
(
4
):
e1
7
.
[PubMed]
1555-2101
45.
Diamond
PR
,
Farmery
AD
,
Atkinson
S
,
Haldar
J
,
Williams
N
,
Cowen
PJ
, et al.
Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic
.
J Psychopharmacol
.
2014
Jun
;
28
(
6
):
536
44
.
[PubMed]
1461-7285
46.
Shiroma
PR
,
Albott
CS
,
Johns
B
,
Thuras
P
,
Wels
J
,
Lim
KO
.
Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression
.
Int J Neuropsychopharmacol
.
2014
Nov
;
17
(
11
):
1805
13
.
[PubMed]
1469-5111
47.
Zarate
CA
 Jr
,
Singh
JB
,
Carlson
PJ
,
Brutsche
NE
,
Ameli
R
,
Luckenbaugh
DA
, et al.
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression
.
Arch Gen Psychiatry
.
2006
Aug
;
63
(
8
):
856
64
.
[PubMed]
0003-990X
48.
Zarate
CA
 Jr
,
Brutsche
NE
,
Ibrahim
L
,
Franco-Chaves
J
,
Diazgranados
N
,
Cravchik
A
, et al.
Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial
.
Biol Psychiatry
.
2012
Jun
;
71
(
11
):
939
46
.
[PubMed]
1873-2402
49.
Murrough
JW
,
Iosifescu
DV
,
Chang
LC
,
Al Jurdi
RK
,
Green
CE
,
Perez
AM
, et al.
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial
.
Am J Psychiatry
.
2013
Oct
;
170
(
10
):
1134
42
.
[PubMed]
1535-7228
50.
Shiroma
PR
,
Johns
B
,
Kuskowski
M
,
Wels
J
,
Thuras
P
,
Albott
CS
, et al.
Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression
.
J Affect Disord
.
2014
Feb
;
155
:
123
9
.
[PubMed]
1573-2517
51.
Cosci
F
,
Chouinard
G
.
Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications
.
Psychother Psychosom
.
2020
;
89
(
5
):
283
306
.
[PubMed]
1423-0348
52.
Price
RB
,
Duman
R
.
Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model
.
Mol Psychiatry
.
2020
Mar
;
25
(
3
):
530
43
.
[PubMed]
1476-5578
53.
Hasler
G
.
Toward specific ways to combine ketamine and psychotherapy in treating depression
.
CNS Spectr
.
2020
Jun
;
25
(
3
):
445
7
.
[PubMed]
1092-8529
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.